|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sjo OH, Berg M, Merok MA, Kolberg M,
Svindland A, Lothe RA and Nesbakken A: Peritoneal carcinomatosis of
colon cancer origin: Highest incidence in women and in patients
with right-sided tumors. J Surg Oncol. 104:792–797. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mori F, Ferraiuolo M, Santoro R, Sacconi
A, Goeman F, Pallocca M, Pulito C, Korita E, Fanciulli M, Muti P,
et al: Multitargeting activity of miR-24 inhibits long-term
melatonin anticancer effects. Oncotarget. 7:20532–20548.
2016.PubMed/NCBI
|
|
4
|
Patel Y, Shah N, Lee JS, Markoutsa E, Jie
C, Liu S, Botbyl R, Reisman D, Xu P and Chen H: A novel
double-negative feedback loop between miR-489 and the
HER2-SHP2-MAPK signaling axis regulates breast cancer cell
proliferation and tumor growth. Oncotarget. 7:18295–18308.
2016.PubMed/NCBI
|
|
5
|
Konishi H, Fujiya M, Ueno N, Moriichi K,
Sasajima J, Ikuta K, Tanabe H, Tanaka H and Kohgo Y: microRNA-26a
and −584 inhibit the colorectal cancer progression through
inhibition of the binding of hnRNP A1-CDK6 mRNA. Biochem Biophys
Res Commun. 467:847–852. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Farazi TA, Spitzer JI, Morozov P and
Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M,
et al: Human microRNA genes are frequently located at fragile sites
and genomic regions involved in cancers. Proc Natl Acad Sci USA.
101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chauhan R and Lahiri N: Tissue- and
serum-associated biomarkers of hepatocellular carcinoma. Biomark
Cancer. 8 Suppl 1:37–55. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Suárez-Arriaga MC, Ribas-Aparicio RM and
Ruiz-Tachiquín ME: MicroRNAs in hereditary diffuse gastric cancer.
Biomed Rep. 5:151–154. 2016.PubMed/NCBI
|
|
11
|
Mohamad M, Wahab NA, Yunus R, Murad NA,
Zainuddin ZM, Sundaram M and Mokhtar NM: Roles of microRNA21 and
microRNA29a in regulating cell adhesion related genes in bone
metastasis secondary to prostate cancer. Asian Pac J Cancer Prev.
17:3437–3445. 2016.PubMed/NCBI
|
|
12
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mukohyama J, Shimono Y, Yamashita K, Sumi
Y, Mukohara T, Minami H and Kakeji Y: Effect of xenotransplantation
site on microRNA expression of human colon cancer stem cells.
Anticancer Res. 36:3679–3686. 2016.PubMed/NCBI
|
|
14
|
Kumar S, Nag A and Mandal CC: A
comprehensive review on miR-200c, a promising cancer biomarker with
therapeutic potential. Curr Drug Targets. 16:1381–1403. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eyking A, Reis H, Frank M, Gerken G,
Schmid KW and Cario E: MiR-205 and miR-373 are associated with
aggressive human mucinous colorectal cancer. PLoS One.
11:e01568712016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vella S, Pomella S, Leoncini PP, Colletti
M, Conti B, Marquez VE, Strillacci A, Roma J, Gallego S, Milano GM,
et al: MicroRNA-101 is repressed by EZH2 and its restoration
inhibits tumorigenic features in embryonal rhabdomyosarcoma. Clin
Epigenetics. 7:822015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Konno Y, Dong P, Xiong Y, Suzuki F, Lu J,
Cai M, Watari H, Mitamura T, Hosaka M, Hanley SJ, et al:
MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation,
invasion and stem cell-like phenotype of aggressive endometrial
cancer cells. Oncotarget. 5:6049–6062. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu L, Beckebaum S, Iacob S, Wu G, Kaiser
GM, Radtke A, Liu C, Kabar I, Schmidt HH, Zhang X, et al:
MicroRNA-101 inhibits human hepatocellular carcinoma progression
through EZH2 downregulation and increased cytostatic drug
sensitivity. J Hepatol. 60:590–598. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kopczyńska E: Role of microRNAs in the
resistance of prostate cancer to docetaxel and paclitaxel. Contemp
Oncol (Pozn). 19:423–427. 2015.PubMed/NCBI
|
|
20
|
Vanas V, Haigl B, Stockhammer V and
Sutterlüty-Fall H: MicroRNA-21 increases proliferation and
cisplatin sensitivity of osteosarcoma-derived cells. PLoS One.
11:e01610232016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao H, Yu X, Ding Y, Zhao J, Wang G, Wu
X, Jiang J, Peng C, Guo GZ and Cui S: MiR-770-5p inhibits cisplatin
chemoresistance in human ovarian cancer by targeting ERCC2.
Oncotarget. 7:53254–53268. 2016.PubMed/NCBI
|
|
22
|
Hu Y, Qiu Y, Yagüe E, Ji W, Liu J and
Zhang J: miRNA-205 targets VEGFA and FGF2 and regulates resistance
to chemotherapeutics in breast cancer. Cell Death Dis. 7:e22912016.
View Article : Google Scholar : PubMed/NCBI
|
